PTAB Remains Unwilling to Deny Inter Partes Review Based on a Contractual Forum-Selection Clause

Nov 16, 2020

Reading Time : 2 min

The contract at issue was a nondisclosure agreement (NDA) that the parties had entered into “for the purpose of sharing confidential information to further [their] business relationship,” including information related to the patent owner’s proprietary technology. The NDA contained a forum selection clause under which the parties “agreed to resolve any disputes regarding the NDA and ‘the transactions contemplated hereby’ . . . in ‘a court of competent jurisdiction, federal or state, located within the Borough of Manhattan, City of New York.’” After the parties’ dealings eventually fell apart, the patent owner sued the petitioner for infringement and breach of contract in New York federal court. The petitioner countered by seeking an IPR on one of the allegedly infringed patents.

Invoking the NDA’s forum selection clause, the patent owner argued that contractual estoppel barred the petition, and it asked the board to deny institution under § 314(a), which allows discretionary denials where the information presented shows that the petitioner lacks a “reasonable likelihood” of success. The patent owner asserted that, although the board previously had rejected similar arguments, it had never “considered whether it may take into account such forum selection clauses under its plenary, discretionary authority . . . to decide when to institute IPR proceedings,” and that “the circumstances in this case warrant [it] doing so.”

In rejecting the patent owner’s contractual estoppel defense, the board first highlighted its prior decisions holding “that contractual estoppel is not a defense to inter partes review.” The board noted that some of those decisions even involved “contractual bar argument[s]” based on forum selection clauses specifically. As the board explained, it is not bound by such clauses and does not have “independent jurisdiction to resolve any contractual dispute” regarding them.

The board next reasoned that the relevant “equitable considerations” under § 314(a)—which include “factors related to . . . efficiency, fairness, and the merits”—did not justify a discretionary denial. The board emphasized that it could not, and would not, blindly accept that the district court in the parallel proceeding likely “would enjoin [the] Petitioner from participating in the IPR,” as the patent owner argued. Rather, the board would have to assess the merits of the patent owner’s estoppel defense, including by interpreting the forum selection clause “and the scope of the parties’ NDA under New York and 2nd Circuit law, as well as [the] Petitioner’s contentions to the contrary.” The board explained that making such determinations would be inconsistent with its prior decisions “expressly declining to consider forum selection clauses,” and that the equitable factors simply did not support denying the petition.

Practice Tip: The board’s ruling is a stark reminder that a contractual forum-selection clause, by itself, likely will not shield a patent owner from inter partes review. Patent owners should keep this in mind, not only when formulating their arguments for opposing an IPR petition, but also when drafting NDAs or other agreements with potential infringers. For instance, a patent owner should additionally consider negotiating for an express covenant not to challenge its patents before the Patent Office. The patent owner may then seek enforcement of such a covenant via injunctive relief in the agreed-upon forum.

 

Case: Samsung Elecs. Am, Inc. v. Kannuu Pty, Ltd., IPR2020-00738, Paper 22 (PTAB Sept. 23, 2020)

Share This Insight

Previous Entries

IP Newsflash

July 22, 2026

The Court of Federal Claims recently denied the United States’ motion to dismiss a patent infringement suit related to production of a COVID-19 vaccine. The court held that it had jurisdiction because the plaintiff filed its claim there before it filed a parallel suit in a district court and because it adequately pleaded the government’s involvement.

...

Read More

IP Newsflash

July 13, 2026

In a precedential and sua sponte Director Review decision, USPTO Director Squires recently vacated three related institution decisions nearly six months after institution where a district court later found the challenged claims invalid. Because the fourteen-day deadline to request Director Review of the institution decisions had passed, the Director used this opportunity to formally extend the deadline in two ways. First, he extended the fourteen-day deadline under 37 C.F.R. § 42.75(c)(1) to thirty days, which “puts requests for Director Review of decisions to institute trial on equal footing to requests for Director Review of final decisions or decisions not to institute trial.” Second, he outlined certain “exceptional circumstances” that warrant a further extension of the deadline to account for changes in the case that “surface after the deadline.” In the case at hand, the Director found the district court’s invalidity finding to be such an “exceptional circumstance” and ultimately initiated review and vacated the institution decisions on that basis.

...

Read More

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.